Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00325689 · ClinicalTrials.gov registry record · Phase 4
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
A Phase 4 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 4
- Development phase
- 323
- Enrollment target
NCT00325689: Completed Phase 4 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT00325689 is a Phase 4 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 323 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (38% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00325689, a Phase 4 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 323 participants
- Enrollment target
Study Summary
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
Interventions
- DRUG Quetiapine or Risperidone + Aripiprazole
- DRUG Quetiapine or Risperidone + placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
What the finished NCT00325689 record still lists
NCT00325689 is an interventional study that assigns participants to a tested intervention. The registered 323 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (38% lower).
The record links to 0 conditions, and to 2 interventions - of which Quetiapine or Risperidone + Aripiprazole is the first listed.
NCT00325689 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00325689 about?
NCT00325689 is a clinical study titled "Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.". A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
What is the current status of trial NCT00325689?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 323 participants. The study started on 2006-07. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00325689?
The interventions under investigation include: Quetiapine or Risperidone + Aripiprazole (DRUG), Quetiapine or Risperidone + placebo (DRUG).
Who is sponsoring clinical trial NCT00325689?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00325689's enrollment target sits among peer trials
323 255th of 2000 higher than 1,744 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia